If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Session Summary
Discover the evolving landscape of psychotropic medications and how new advancements are reshaping mental health treatment. This presentation will delve into dextromethorphan/bupropion, long-acting injectable risperidone, and serdexmethylphenidate/dexmethylphenidate, highlighting their unique benefits and limitations. Gain practical insights into integrating these innovative therapies into clinical practice, potentially enhancing patient outcomes and expanding your treatment toolkit as a psychiatric pharmacist.
Faculty Information
Danielle Stutzman, PharmD, BCPP Daniel McGraw, PharmD, BCPP Frank Tillman III, PharmD, BCPS, BCPP
Danielle Stutzman, PharmD, BCPP
Psychiatric Pharmacist
The Pediatric Mental Health Institute at Children’s Hospital Colorado
Aurora, CO
Danielle Stutzman, PharmD, BCPP is a Clinical Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, an Assistant Adjoint Professor within the Child and Adolescent Mental Health Division Department of Psychiatry at the University of Colorado School of Medicine and serves as a Psychiatric Pharmacist at the Pediatric Mental Health Institute at Children’s Hospital Colorado. Dr. Stutzman serves as an integral member of inpatient, partial hospitalization, and outpatient treatment teams to ensure optimal use of psychotropic medications among children and adolescents. Dr. Stutzman received her bachelor’s degree (molecular cellular developmental biology and psychology) from the University of Colorado at Boulder and her doctoral degree (pharmacy) from the University of Colorado Anschutz Medical Campus. She completed two years of postdoctoral residency training in psychiatric pharmacy at the University of Southern California.
Daniel McGraw, PharmD, BCPP
Clinical Specialist in Psychiatry, Residency Program Director of PGY-2 Psychiatric Residency Program
MUSC Health
Charleston, SC
Dr. Dan McGraw is a clinical pharmacy specialist in psychiatry at MUSC Health, Affiliate Assistant Professor at the MUSC College of Pharmacy, and Adjunct Professor at the MUSC College of Nursing. In addition, he currently serves as the residency program director for the PGY2 Psychiatric Pharmacy Residency program at MUSC Health. He has been in clinical practice at MUSC for 8 years and provides clinical pharmacy services for the adult inpatient general psychiatry population as well as outpatient addiction and mood disorder populations, including a long-acting injection clinic. Dr. McGraw enjoys teaching and precepting and offers a variety of rotation learning experiences to pharmacy students, PGY1s, and PGY2s throughout the year. Dr. McGraw is a graduate of MUSC College of Pharmacy and completed residency training in psychiatric pharmacy practice at MUSC. While not at work, Dan enjoys spending quality time with his wife and young son, Teddy.
Frank Tillman III, PharmD, BCPS, BCPP
Clinical Pharmacy Practitioner in Mental Health
Durham VA Healthcare System
Durham, NC
Frank Tillman III, PharmD, BCPS, BCPP, is a Clinical Pharmacy Practitioner in Mental Health at Durham VA Healthcare System. Dr. Tillman serves as an integral member of the outpatient Behavioral Health Interdisciplinary Program (BHIP) and Treatment Resistant Disorders (TRD) clinics where he provides comprehensive medication management for Veterans with mental health conditions. He is highly passionate about improving patient outcomes through evidence-based practices and has a strong background in managing complex medication therapies and providing clinical education for a wide array of postgraduate trainees. His commitment to advancing the field of pharmacy is evident through his leadership, mentoring, and dedication to continuous learning. Frank's professional interests include direct patient care, clinical research, clinical education, health equity, and professional well-being.
Dr. Tillman received a Bachelor of Arts degree in interpersonal/organizational communication studies from the University of North Carolina (UNC) at Chapel Hill and a Doctor of Pharmacy degree from the UNC Eshelman School of Pharmacy. After completing pharmacy school, Frank completed a PGY1 pharmacy residency in acute care and a PGY2 pharmacy residency in psychiatry at UNC Medical Center. He is a Board Certified Pharmacotherapy and Psychiatric Specialist. In his spare time, he enjoys spending quality time with his family and friends, exercising, traveling, and finding exciting places to indulge in great food and art.
Learning Objectives
Identify the clinical advantages and/or disadvantages of newer psychotropic medications.
Discuss practical application and where newer psychotropic medications fit into clinical practice.
Continuing Education Credit and Disclosures
Activity Dates: 04/29/2025 - 04/29/2028 ACPE Contact Hours: 1 ACPE Number: 0284-0000-25-019-H01-P (Knowledge) Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.